Next Article in Journal
Flow Injection Spectrophotometric Determination of N-Acetyl-L-cysteine as a Complex with Palladium(II)
Next Article in Special Issue
Synthesis of Quinolin-2-one Alkaloid Derivatives and Their Inhibitory Activities against HIV-1 Reverse Transcriptase
Previous Article in Journal
Chirality and Numbering of Substituted Tropane Alkaloids
Previous Article in Special Issue
Anti-Inflammatory Effect of Myristicin on RAW 264.7 Macrophages Stimulated with Polyinosinic-Polycytidylic Acid
Article

Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes

Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba, Ibaraki, Japan
*
Author to whom correspondence should be addressed.
Molecules 2011, 16(9), 7210-7223; https://doi.org/10.3390/molecules16097210
Received: 26 July 2011 / Revised: 4 August 2011 / Accepted: 22 August 2011 / Published: 25 August 2011
(This article belongs to the Special Issue Antivirals)
ASP2151 is a herpesvirus helicase-primase inhibitor with antiviral activity against varicella zoster virus and herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). Here, we examined the potency and efficacy of ASP2151 against HSV in vitro and in vivo. We found that ASP2151 was more potent in inhibiting the replication of HSV-1 and HSV-2 in Vero cells in the plaque reduction assay and had greater anti-HSV activity in a guinea pig model of genital herpes than did acyclovir and valacyclovir (VACV), respectively. Oral ASP2151 given from the day of infection reduced peak and overall disease scores in a dose-dependent manner, resulting in complete prevention of symptoms at the dose of 30 mg/kg. The 50% effective dose (ED50) values for ASP2151 and VACV were 0.37 and 68 mg/kg, respectively, indicating that ASP2151 was 184-fold more potent than VACV. When ASP2151 was administered after the onset of symptoms, the disease course of genital herpes was suppressed more effectively than by VACV, with a significant reduction in disease score observed one day after starting ASP2151 at 30 mg/kg, whereas the therapeutic effect of VACV was only evident three days after treatment at the highest dose tested (300 mg/kg). This indicated that ASP2151 possesses a faster onset of action and wider therapeutic time window than VACV. Further, virus shedding from the genital mucosa was significantly reduced with ASP2151 at 10 and 30 mg/kg but not with VACV, even at 300 mg/kg. Taken together, our present findings demonstrated the superior potency and efficacy of ASP2151 against HSV. View Full-Text
Keywords: ASP2151; amenamevir; antiviral; HSV; guinea pig; genital herpes ASP2151; amenamevir; antiviral; HSV; guinea pig; genital herpes
Show Figures

Figure 1

MDPI and ACS Style

Katsumata, K.; Chono, K.; Sudo, K.; Shimizu, Y.; Kontani, T.; Suzuki, H. Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes. Molecules 2011, 16, 7210-7223. https://doi.org/10.3390/molecules16097210

AMA Style

Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H. Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes. Molecules. 2011; 16(9):7210-7223. https://doi.org/10.3390/molecules16097210

Chicago/Turabian Style

Katsumata, Kiyomitsu, Koji Chono, Kenji Sudo, Yasuaki Shimizu, Toru Kontani, and Hiroshi Suzuki. 2011. "Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes" Molecules 16, no. 9: 7210-7223. https://doi.org/10.3390/molecules16097210

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop